Descriptor: 10.4 Diagnosis of Infections
ABSTRACT:
BACKGROUND: Lower respiratory tract infections (LRTI) are a leading cause of mortality in hematopoietic cell transplant (HCT) recipients. Current microbiologic diagnostics often fail to identify etiologic pathogens, leading to diagnostic uncertainty and precluding the implementation of targeted therapies. To directly address the need for improved LRTI diagnostics, we undertook this study to evaluate the potential utility of metagenomic next generation sequencing (mNGS) approaches for detecting LRTI in the HCT population.
METHODS:
We enrolled 22 post-HCT adults ages 19-69 years with acute respiratory illnesses who underwent bronchoalveolar lavage (BAL) at the University of Michigan between January 2012 and May 2013. Unbiased mNGS was performed on BAL fluid to detect microbes and assess host response. Results were compared to those obtained by standard clinical microbiology testing.
RESULTS:
Unbiased mNGS detected all microbes identified by standard testing (human metapneumovirus, respiratory syncytial virus, Stenotrophomonas maltophilia, human herpesvirus 6 and cytomegalovirus). Previously unrecognized LRTI pathogens were identified in six patients for whom standard testing was negative (human coronavirus 229E, human rhinovirus A, Corynebacterium propinquum and Streptococcus mitis) and findings were confirmed by independent PCR testing. mNGS identified microbes of unlikely or uncertain pathogenicity in 10 patients with clinical evidence of non-infectious respiratory conditions. Patients with respiratory pathogens were found to have significantly increased expression of immunity related gene biomarkers relative to those without (p=0.022) as well as lower alpha diversity of their respiratory microbial communities (p=0.017).
CONCLUSIONS:
Compared to conventional diagnostics, host/pathogen mNGS enhanced detection of microbial pathogens in BAL fluid from HCT patients. Furthermore, this approach simultaneously evaluated the association between identified microbes and the expression of innate immunity gene biomarkers. Host/pathogen mNGS holds promise for precision diagnosis of post-HCT respiratory infection.
INTRODUCTION:
Lower respiratory tract infections (LRTI) are a leading cause of both hospitalization and mortality in hematopoietic cellular transplantation (HCT) recipients (1) (2) (3) . This problem is underscored by autopsy studies showing that 30% of HCT patients had previously undetected pulmonary pathogens that likely contributed to death (4, 5) . Despite this, the etiologic pathogens remain unidentified in most cases due to the limitations of current microbiologic tests in terms of sensitivity, speed and limited number of available targets (6) .
Diagnosis of LRTI in HCT recipients is particularly challenging due to high rates of non-infectious inflammatory conditions such as graft versus host disease (GVHD) that can drive pulmonary inflammation, induce fever and mimic infection (7) (8) (9) (10) . Furthermore, the diagnostic yield of traditional tests is reduced in HCT patients due to antimicrobial prophylaxis, reduced antibody titers, and infections from uncommon opportunistic microorganisms (11, 12) .
The limitations of current microbiologic tests drive excess use of empiric broadspectrum antimicrobials, which potentiates the emergence of drug resistance and increases risk of Clostridium difficile infection (13) . In some situations, empiric regimens may lack activity against the underlying microbe, resulting in delayed effective treatment, disease progression, and consequent adverse outcomes (6, 14) . Furthermore, in transplant patients, concern for GVHD may compel clinicians to initiate empiric immunosuppressive agents that could inadvertently exacerbate disease in the presence of unrecognized infection (15) .
Previously, microarray approaches proved useful for broadening the scope of pathogens detectable in a single LRTI assay, but were limited to detection of a priori selected targets (16) . Metagenomic next-generation sequencing (mNGS) now offers significantly enhanced diagnostic capabilities by providing a culture-independent, comprehensive measurement of the microbial composition (17) (18) (19) (20) (21) (22) . This technology permits the simultaneous detection of bacterial, viral and fungal pathogens without introducing bias associated with fixed-target PCR or serologic assays (16, 18, 20, 22) . By capturing both microbial and human RNA, mNGS also permits simultaneous transcriptional profiling of the host immunologic response associated with the presence and type of infection, and thus provides complementary insight regarding pathogenesis (6, (23) (24) (25) . Due to the clear need for enhanced respiratory pathogen diagnostics in HCT recipients, we undertook this study examining the utility of host/pathogen mNGS for detection of LRTI pathogens in HCT patients hospitalized with acute respiratory illnesses.
MATERIALS AND METHODS:

Subjects:
This retrospective study evaluated randomly chosen adult HCT recipients who underwent bronchoscopy with bronchoalveolar lavage (BAL) at the University of Michigan Medical Center between January 25 th , 2012 and May 20 th , 2013. All patients met clinical definitions of community or hospital-acquired pneumonia that included cough plus fever, sputum production, breathlessness, wheeze, chest discomfort or pain and had evidence of lower respiratory tract involvement on chest imaging. In some cases patients had other equally probable non-infectious explanations for respiratory symptoms (26) (27) (28) (29) (30) . All subjects had routine microbiological testing of BAL fluid as part of standard of care diagnostic workup for respiratory illness. Patients consented to permit banking of surplus BAL specimens in a biorepository at -80°C in accordance with University of Michigan IRB protocol HUM00043287. De-identified samples were then transported to UCSF for mNGS. The UCSF study team was blinded to the characteristics and outcomes associated with each patient were blinded to the study team until after mNGS data analysis was completed.
Clinical Microbiologic Testing
During the period of study enrollment, standard-of-care clinical microbiological diagnostic testing for respiratory infections included bacterial, mycobacterial and fungal cultures, CMV shell viral culture, Aspergillus galactomannan assay, multiplex PCR for influenza A/B, respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), human herpesvirus-6 (HHV-6) PCR, and silver stain for Pneumocystis jiroveci. Additional studies included nasophayngeal (NP) swab PCR for influenza A/B, RSV, and HMPV, blood cultures, serum PCR for herpes simplex virus (HSV) types 1 and 2, varicella-zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and HHV-6, Clostridium difficile toxin stool PCR, and select additional studies on BAL per the clinical judgment of the treating physicians.
Metagenomic Next-Generation Sequencing
Total nucleic acid was extracted from 250µl of patient BAL fluid using bead-based lysis and the Zymo Viral DNA/RNA Kit (Zymo Research). RNA and DNA were isolated separately using DNAse or RNAse, respectively, and the former was reverse transcribed to generate complementary DNA (cDNA). DNA and cDNA then underwent adapter addition and barcoding using the Nextera system (Illumina). Depletion of abundant sequences by hybridization (DASH) was used to selectively deplete human mitochondrial cDNAs from the tagmented library, thus enriching the mNGS libraries for non-human sequences (31) . The final RNA sequencing (RNAseq) and DNA sequencing (DNAseq) libraries underwent 135 nucleotide paired-end sequencing on an Illumina HiSeq 4000 Please refer to Supplemental Text for further description.
Pathogen Detection Bioinformatics
Detection of microbial pathogens leveraged a custom bioinformatics pipeline that incorporates Bayesian modeling to discriminate pathogens from background microbial sequences (32) . Briefly, this analytical approach involved first filtering for quality and complexity, next extracting sequences aligning to the human genome (NCBI GRC h38) using STAR (33) and then subsequently removing reads aligning to non-fungal eukaryotes, phage, nonhuman tropic viruses using Bowtie2 (34) as well as contaminants in water controls. The identities of the remaining reads were determined by querying the NCBI nucleotide (nt) and non-redundant protein (nr) databases using GSNAP-L. Please refer to Supplemental Text for further description.
For each subject, microbial taxa at the genus level were assigned a microbial significance score based on the product of (1) the reads per million RNA transcripts sequenced (rpM) and (2) a composite genus Z-score reflecting the relative abundance of transcripts in the nt and nr databases compared to all other patients in the cohort: score = rpM x (Z nt + Z nr ). To reduce spurious alignments, we required (1) bacteria and fungi detected by RNAseq to also have detectable genomes by DNAseq, (2) microbes to be detected by both nt and nr databases, and (3) microbes to have a Z nt and Z nr greater than zero. Viral pathogens not previously identified by standard clinical testing were confirmed by independent specific PCR testing. 16s rRNA gene sequencing (University of Washington) was used to confirm identification of top ranking bacterial pathogens at the genus level. Finally, alpha diversity of the respiratory microbiome in each subject was assessed using the Simpson Diversity Index (SDI) (35) .
Definitions
Subjects were grouped into one of three categories based on microbiologic results. Confirmed pathogen if both clinical testing and mNGS identified a microbe with established pathogenicity in the lungs and the pathogen scored 10-fold greater than any other microbe identified by mNGS (26) . New potential pathogen if previously occult microbes were detected by mNGS with literature evidence of pathogenicity in the lungs and with a score 10-fold greater than any other microbe of the same type, in terms of virus, bacteria or fungus. Unlikely or uncertain pathogen if microbes detected by any method were: a) not known to exist as pulmonary pathogens, b) potential pathogens but scoring 10-fold less than the top-ranking microbe as part of a polymicrobial sample, c) determined to be clinically insignificant by the treatment team, d) known to be a common laboratory contaminant, or e) a DNA virus of uncertain pathogenicity present in low abundance.
Host gene expression analyses
RNA transcripts aligning to the human genome were captured by our computational pipeline as described above. Cumulative sum scaling normalization of protein coding gene transcripts was carried out (36) and genes expressed in fewer than 30% of samples or as outliers in only 10% of samples were removed. Using a supervised approach, pathways related to immune functionality were selected a priori from the Molecular Signatures Database (37) and compared in terms of total normalized expression between subjects using the nonparametric Wilcoxon Rank Sum test (Supplemental Text and Table S4 ). These pathways contained gene biomarkers associated with antiviral response, interferons α, β, and γ, IL-6/JAK/STAT5 signaling and adaptive immunity, and have all been strongly associated with the immune response to infection (38, 39) .
RESULTS:
Cohort characteristics and clinical outcomes
We enrolled 22 HCT recipients hospitalized for acute respiratory symptoms aged 19-69 years at a median 356 days post-transplant ( Table 1) . Their most common transplant indications were leukemia (n=12) and lymphoma (n=8). The majority of patients received allogeneic HCT (n=20) and/or myeloablative conditioning (n=20 , Table S1 ). The median absolute neutrophil count (ANC) at the time of BAL was 3.8/µL (IQR 2.1-5.4) and engraftment was achieved at the time of BAL in all patients. Acute GVHD was present in 3 subjects and chronic GVHD was present in 13 subjects. At the time of BAL, immune modulating agents were used for GVHD prophylaxis or treatment in 15 allogeneic recipients.
Fever was present in 57% of patients, all patients met systemic inflammatory response syndrome criteria, and no patients had septic shock. Twelve patients required supplemental oxygen, three required mechanical ventilation and all survived their illnesses except for one subject who died 10 days after BAL due to lymphoma relapse ( Table 1) . Seven subjects died between 51 and 3024 days later and their primary causes of death were GVHD (n=3), relapsed malignancy (n=2), and idiopathic pulmonary failure (n=1).
Antimicrobial use
All study subjects received antimicrobial prophylaxis prior to symptom onset and bronchoscopy. Empiric antibiotics were used in 16 patients including vancomycin (n=4), cefepime (n=4), vancomycin + cefepime (n=5), cefepime + tobramycin (n=1), and vancomycin + cefepime + tobramycin (n=1) ( Table 1) . Targeted antimicrobials were used in three subjects (TMP-SMZ for Stenotrophomonas maltophilia, foscarnet for HHV-6 and ribavirin for RSV). Four patients received no antimicrobials aside from pre-existing prophylactic agents.
Clinical Microbiologic Findings
Standard-of-care clinical BAL diagnostics performed at the study hospital (see methods) identified microbes in seven patients, of which six were thought to represent etiologic pathogens by the treating physicians. These included HMPV (n=2), RSV (n=2), HHV-6 (n=1) and Stenotrophomonas maltophilia (n=1). CMV was identified by shell vial culture in subject 37 but through to represent incidental carriage because of symptom resolution in the absence of intervention prior to the return of testing.
Next Generation Sequencing Findings
An average of 49 million paired-end sequencing reads were generated from each BAL sample, of which <1% were microbial (Table S2) . mNGS identified all 7 microbes found by standard clinical diagnostics. In total, RNAseq identified 10 RNA viruses, all of which have established pathogenicity in the lungs and five DNA viruses of questionable pulmonary pathogenicity. DNAseq identified the genomes of these five DNA viruses as well as five others including CMV and HHV-6, which have been associated with pneumonitis. Bacteria known to exist contextually as either pathogens or commensals, including Stenotrophomonas maltophilia, Streptococcus mitis, and Corynebacterium propinquum were identified, as were genera not typically considered pathogenic (40) (41) (42) . mNGS captured entire viral genomes for five patients at an average read depth of 3500 fold ( Figure S1 ).
Relationship Between Respiratory Microbial Diversity and Detection of Pathogens
Loss of diversity within respiratory tract microbial communities has been proposed as an ecological marker of infection (43, 44) . We thus evaluated alpha diversity of actively replicating microbes between subjects by SDI and found that subjects with confirmed pathogens had significantly lower alpha diversity relative to patients with only microbes of unlikely pathogenicity (0.34 (IQR 0.15-0.64, n=6) vs. 0.92 (IQR 0.86-0.93, n=10), p=0.017, Figure 2 and Table S3 ). Reduced diversity was also observed if subjects with confirmed or potential new pathogens were compared together against those without (0.41 (IQR 0.20-0.55, n=12) vs. 0.92 (IQR 0.86-0.93, n=10), p<0.001, Figure 2 and Table S3 ).
Analysis of Host Gene Expression
We hypothesized that gene expression from respiratory fluids obtained at the site of infection would distinguish patients with LRTI from those with non-infectious respiratory diseases. To test this idea, we evaluated a priori selected gene biomarkers of innate and adaptive immune responses using the total normalized expression of all genes. Given the heterogeneity of the infectious processes (bacterial and viral) and possible host responses (anti-bacterial, anti-viral) involved, we created a composite metric based on the sum normalized gene expression of all biomarkers. We found significantly increased expression in patients with confirmed LRTI pathogens versus those without (p=0.022, Figure 3 , Table S4 ). When patients with confirmed or potential new pathogens were compared to those without a potential or confirmed infection, the relationship trended towards significance (94.6 (IQR 76.5-10.5, n=11) vs. 33.1 (IQR 20.7-75.1, n=7), p=0.0634), but reached significance (p = 0.014) if an individual subject with relatively lower abundance HRV-A sequences was grouped amongst those with microbes of uncertain or unlikely pathogenicity (Figure 3, Table S4 ).
DISCUSSION:
In this proof of concept study, we demonstrate that unbiased mNGS can simultaneously detect pathogens and the host response in HCT patients with acute respiratory diseases. mNGS of respiratory fluid RNA and DNA permitted identification of new potential viral and bacterial pathogens in 6 of the 15 (40%) subjects with otherwise negative conventional testing. In addition, we observed that the presence of respiratory pathogens was characterized by increased expression of host immune response genes and lower airway microbial diversity. Our results describe a novel diagnostic approach that not only identifies respiratory microbes but also simultaneously assays the host's immunologic response and airway microbiome composition to provide complementary data regarding the clinical significance of the detected agent.
When benchmarked against the conventional standard of care testing performed during the time of study enrollment, mNGS yielded 100% sensitivity for microbial detection. In addition, mNGS confirmed clinically suspected LRTI in one patient with a positive HMPV nasopharyngeal PCR but negative BAL testing. CMV was identified by both viral culture and mNGS, however this finding was considered unrelated to the patient's respiratory illness by the treating physicians. Interestingly, while CMV was detected by DNAseq, no RNA transcripts were identified, suggesting that it may have represented incidental carriage as opposed to a transcriptionally active pathogen (45, 46) .
Amongst the cases with negative clinical testing, mNGS identified six patients harboring transcriptionally active microbes described as respiratory pathogens in the literature (47-52). HCOV-229E was identified in two patients and HRV-A was identified in three patients, one of whom was also culture-positive for Stenotrophomonas maltophila. The presence of these viruses, confirmed by independent PCR testing, was presumably missed because HRV and HCOV were not represented on the multiplex PCR panel used at the study hospital. The fact that many clinical laboratories still do not routinely test for these viruses highlights the utility of a single unbiased mNGS assay for detecting respiratory microbes. Unlike rapid antigen or multiplex PCR assays, mNGS is not limited to a fixed number of pre-specified targets on a panel, obviating the need to order multiple independent diagnostic tests. Furthermore, mNGS permits detection of complete viral genomes (Figure S1 ), an attribute that can enable genotyping, detection of resistance mutations, and epidemiologic tracking of disease outbreaks (53).
With respect to previously unidentified bacterial pathogens, mNGS detected Streptococcus mitis, an oropharyngeal microbe known to cause bacteremia and acute respiratory distress in HCT recipients, as the most abundant BAL microbe in one patient with idiopathic acute respiratory symptoms (52, 54). Corynebacterium propriniquum, one of the few virulent Corynebacterium sp. associated with LRTI, comprised the majority of microbial transcripts in another subject's BAL fluid (44, (47) (48) (49) . Both patients received empiric vancomycin, which has activity against Streptococcus and Corynebacteria spp., and recovered from their acute respiratory illnesses. Findings were independently confirmed at the genus level by 16s rRNA gene sequencing.
Ten patients with negative conventional testing were found to have microbes of uncertain or unlikely pathogenicity. Notably, each of these patients had potential alternative explanations for their respiratory symptoms. While one of these patients had bacteremia/sepsis, the remaining nine had acute and/or chronic GVHD, underlining the importance of non-infectious alloreactive inflammation in post-HCT pulmonary complications.
Metagenomic NGS identified a number of viruses with DNA genomes, however only five of these also had well-defined evidence of active replication marked by detectable RNA transcripts (HSV, human papilloma virus and torque teno viruses (TTV, n=3). TTV was the most commonly detected DNA virus, a finding consistent with prior reports demonstrating an increased prevalence of this presumptively innocuous constituent of the human virome in immunosuppressed patients (55-57). Herpesviridae genomic DNA in the absence of viral transcripts was identified in five patients and included HHV-6 (n=1), CMV (n=2), HSV (n=1) and EBV (n=1). The one subject who died 10 days post-BAL due to relapsed lymphoma had EBV DNA detected in the setting of EBV viremia. WU polyoma virus was detected by DNA sequencing in one of these subjects, and while this virus has been associated with respiratory infections in immunocompromised patients, evidence supporting its role as a pathogen is lacking (58).
With respect to bacteria of uncertain or unlikely pathogenicity, several taxa representing common constituents of the oropharyngeal or respiratory microbiome, including Rothia, Prevotella and Actinomyces and others, were identified ( Table S2) . The majority were found at relatively low or equal abundance by both RNAseq and DNAseq, suggesting that they did not represent dominant, actively replicating pathogens but instead normal flora (Table S2) . Lactobacillus was identified in one patient with a Gram-positive rod bacteremia that was not further speciated. It is possible that mNGS may have value as a complementary method for ruling out infection or de-escalating antimicrobials in patients with negative culture or PCR-based assays and microbes of unlikely pathogenicity detected by mNGS (59).
Lung microbiome diversity and the host immune response as biomarkers of infection
Because asymptomatic carriage of respiratory pathogens is well described (60-62), establishing biomarkers of genuine infection is critical for determining whether a given microbiologic finding is clinically significant. Our findings suggest that respiratory tract microbial diversity may be such a biomarker. Specifically, we found that patients with LRTI pathogens had significantly lower alpha diversity versus those without (p=0.016, Figure  2 , Table S3 ), presumably reflecting dominance of actively replicating pathogens (43, 44) .
Our results also demonstrate that both mNGS and conventional methods identify clinically significant and insignificant microbes, and emphasize the need to assess the impact of a given microbiologic finding in the context of a patient's immunologic response (6, 63) . We found that that simultaneous assessment of host gene expression by mNGS can potentially serve as a biomarker for distinguishing infection from non-infection (e.g. colonization). Expression of a multi-gene immune response composite metric was significantly increased in patients with confirmed respiratory pathogens relative to those without, suggesting that despite significant and heterogeneous states of immune suppression, HCT recipients still exhibited immunologic biomarkers of active infection (p=0.022, Figure 3 ).
Amongst subjects with potential new pathogens, we observed that two of the three HRV-A positive subjects demonstrated the lowest expression of this immune response metric, while the remaining subject, who was co-infected with HRV-A and Stenotrophomonas maltophila, had one of the highest values. This is consistent with prior reports demonstrating that HRV can induce a broad range of clinical disease severity, and that viral-bacterial co-infection can increase the severity of infection and tissue injury (60, 62). Additional prospective studies are needed to validate this metric and develop robust gene classifiers that differentiate LRTI from non-infectious lung disease in HCT recipients with acute respiratory symptoms.
By enhancing pathogen detection or by confirming negative results of conventional assays, mNGS may prove useful for reducing excessive broadspectrum antibiotic which is often driven by suspicion for occult bacterial pathogens missed by standard testing. For instance, subject 1, whose testing identified only HMPV, received empiric vancomycin and cefepime due to suspected, but occult bacterial infection, and subsequently developed C. difficile colitis. mNGS confirmed the presence of HMPV and also demonstrated absence of bacterial pathogens in this patient. The theoretical availability of our mNGS findings during the actual period of patient hospitalization potentially could have informed more targeted antimicrobial use in 18 study subjects who received broad-spectrum antibiotics in the absence of detectable bacterial pathogens.
Many HCT recipients with unexplainable acute respiratory illnesses receive a diagnosis of Idiopathic Pneumonia Syndrome (IPS), a post-HCT condition that is characterized by acute lung injury and clinical features of pneumonia in the absence of a detectable pathogen (9) . In our cohort, 17 (77%) subjects fulfilled IPS criteria and of these, mNGS identified possible pathogens in six (35%) cases, consistent with findings from a recent report (64).
This proof of concept study was limited by a relatively small sample size, only one case of culture-positive bacterial LRTI, no cases of fungal infection, and focused exclusively on subjects with inflammatory airway disease. Future studies with larger cohorts will be needed to validate the sensitivity and specificity of mNGS for LRTI diagnosis in this population. Second, our limited sequencing depth did not provide the human transcriptome coverage needed for statistically robust differential gene expression analyses, although we could rigorously evaluate a composite metric of immunity genes. Future studies that include a healthy control group without inflammatory lung disease are needed to identify and validate gene classifiers that can distinguish LRTI from noninfectious airway diseases in HCT recipients.
CONCLUSIONS:
Here we leverage continued improvements in genome sequencing to expand the capabilities of LRTI diagnostics in HCT recipients with acute respiratory illnesses. We demonstrate that compared to current microbial diagnostics, mNGS has a greater capacity for detecting microbes and an ability to couple pathogen detection with simultaneous profiling of the host response and the airway microbiome. Subsequent evaluation in a larger prospective cohort will be needed to validate these findings, define a genomic classifier for LRTI and evaluate the clinical impact of mNGS respiratory infection diagnosis in HCT recipients and other high-risk populations. Table S4 .
